Sabinsa Secures Patent From Republic of South Africa on Psoriasis

Sabinsa Corporation announced today that it has secured a patent from the Republic of South Africa for its natural proprietary composition with clinically proven efficacy and safety in the treatment of psoriasis. The South African Patent #2007/0694, titled "Compositions And Methods For The Management Of Hyperproliferative Dermatological Conditions," describes the composition and its method of use in treating psoriasis. Sabinsa also has other worldwide patents pending on this composition.

"For several years now, we have been on a quest to find a remedy for this disease [psoriasis] with a natural complex; we're proud to have finally achieved this," said Muhammed Majeed, Ph.D, founder and owner of Sabinsa Corporation. "Unlike many of the drugs available for psoriasis, our product did not show any untoward side effects in any of our clinical trials."

Psoriasis is a non-contagious, lifelong skin disease that causes red, scaly patches called lesions to appear on any area of the skin. According to the National Institutes of Health, as many as 7.5 million Americans suffer from psoriasis. Psoriasis affects nearly three 3 percent of the world's population. It can develop in males or females of any race or age. It often appears between the ages of 15 and 35, although it can strike at any age, including infants and the elderly. Psoriasis can range from mild or moderate to very severe and disabling. According to the National Psoriasis Foundation, about 56 million hours of work are lost each year by people who suffer from psoriasis, and between $1.6 billion and $3.2 billion is spent per year to treat psoriasis.

Sabinsa Corporation is a manufacturer and supplier of herbal extracts, cosmeceuticals, minerals and specialty fine chemicals. Celebrating its 20th year servicing the natural products industry, Sabinsa's mission is to provide alternative and complementary natural products for human nutrition and wellbeing. Over the past several years, the company has brought to market more than 50 standardized botanical extracts and privately funded several clinical studies in conjunction with prestigious institutions in support of these products. With more than 100 scientists working full time conducting ongoing research both in India and the United States, Sabinsa continues to develop and patent phytonutrients for the world market. Sabinsa has six state-of-the-art manufacturing facilities in India dedicated to the production of herbal extracts, phytochemicals, biotech ingredients and supercritical extracts. In the U.S., the company operates a 42,000-square-foot facility in Payson, Utah, which provides cutting-edge capabilities for the development of capsules, tablets, bulk custom pre-mixes, drum-to-hopper blends, stick packs and powdered drinks. All of Sabinsa's facilities use effluent water treatment systems and are environmentally conscious and friendly. All products are intended for human consumption and certified Kosher. For more information visit www.sabinsa.com.